BCL2 and neoplasm: Isovitexin reduces the levels of p-PI3K, p-Akt, p-mTOR, and Bcl-2 in tumor tissues, thereby inhibiting the migration, invasion, and EMT of cancer cells (Zhu et al., 2021).